

## **ROUND 1**

To,

Lian-Sheng Ma, Science Editor, Company Editor-in-Chief, Editorial Office

Baishideng Publishing Group Inc

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-399-1568

E-mail: [l.s.ma@wjgnet.com](mailto:l.s.ma@wjgnet.com)

Regarding: Manuscript NO.: 68591, “Fondaparinux in Acute Coronary Syndromes”

Dear Editor,

The authors thank the editorial board from The World Journal of Cardiology for their time and valuable suggestions for enhancing the scientific value and readability of the above-mentioned manuscript. Please find our point-by-point responses to the editorial board comments.

We hope we have fully addressed the concerns, and that the manuscript will now be considered suitable for publication.

Please feel free to contact me if needed.

Thank you,

Dr. Mohammed Yunus Khan,

doctorkhan26@gmail.com

## **Authors' Responses to Editorial Board Comments**

*Journal:* The World Journal of Cardiology

*Manuscript NO.:* 68591

**Comment 1:** The authors have addressed comments below, thank you.

*Would you please kindly correct all your typos and grammar errors throughout the manuscript.*

**Response:** For comment 1: We have revised and also run the manuscript through a professional editing service to fix these issues.

**Comment 2:** The paper is built as a systematic review but would you please kindly write down a sort of Introduction with a clear objective

**Response:** For comment 2: Please see highlighted yellow section, we have expanded introduction with objective.

**Comment 3:** Please harmonize the paper in the sense of what you are writing about. What is the idea of the subtitle “antithrombotic therapy”? Would you talk about antiplatelet drugs as well? It looks like your review about anticoagulant treatment exceptionally! Please, be focused on the topic

**Response:** For comment 3: Please see highlighted in yellow, we have edited the title to reflect accuracy.

**Comment 4:** It would help if you had more remarks about pathogenesis in your introduction to adequately justify the need for anticoagulants, maybe with a scheme. I see your figure 1, but can you upgrade it to understand why fondaparinux is essential.

**Response:** Please see highlighted in yellow we have added details about pathogenesis in introduction.

**Comment 5:** What is that supposed to mean when you call fondaparinux a new anticoagulant? It is not new already for years, even decades. Please, mention the history of this drug in the article. It must be clear for a reader what is the clinical value of this drug today.

**Response:** Please see highlighted in yellow we have added the details. Thanks.

**Comment 6:** There must be a paragraph with an analysis of the international guidelines separately. Please, justify why guidelines recommend fondaparinux only in specific clinical scenarios. In table 10, you don't have any recent guidelines. But there are a few of them with a reconsidered vision on fondaparinux.

**Response:** We have updated these in the manuscript. As well as added an additional table to clarify this point.

**Comment 7:** Tables: there is no summarized value of fondaparinux. I would strongly recommend you make a table merging and matching the performance of fondaparinux in the

different studies as a sort of the summary ideally with all the pros and cons (including “negative”/ “alarming” outcomes - I am about bleeding, first of all).

**Response:** We have added text and updated table to answer this comment.

**Comment 8:** Figures 3 and 4 are not readable. I would recommend you correcting the format for the Journal.

**Response:** We have updated these figures.

**Comment 9:** The general impression is that your analysis is slightly outdated. Please provide a reader with up-to-date information, including all the remarks and substudies in the field. Some of your current points are from the age of 2002-2007, like nothing happened after that.

**Response:** We have included studies from 2014 onwards as well.

Science Editor comments:

**Comment 1:** The authors did not provide original pictures. Please provide the original figure documents. Please prepare and arrange the figures using PowerPoint to ensure that all graphs or arrows or text portions can be reprocessed by the editor.

**Response:** We have uploaded accordingly.

**Comment 2:** PMID and DOI numbers are missing in the reference list. Please provide the PubMed numbers and DOI citation numbers to the reference list and list all authors of the references. Please revise throughout

**Response:** We have updated accordingly.

**Comment 3:** If an author of a submission is re-using a figure or figures published elsewhere, or that is copyrighted, the author must provide documentation that the previous publisher or copyright holder has given permission for the figure to be re-published; and correctly indicating the reference source and copyrights

**Response:** No figures have been re-used. Thank you.

## **ROUND 2**

No. Comments by reviewer Reply by the Author 1 I did not find any figures or tables in the submitted documents Figures and tables are added at the last after references in Manuscript document which is uploaded now as per the template given.

2 Your language requires some brushing-up. Language is amended and is explanatory.

3 The introduction has neither any justification of your topic not objective yet Justification and Objective added.

4 What is that supposed to mean “a newer anticoagulant”?! This part describes the clinical Pharmacology of the drug and thus the heading is being amended.

5 Please, use the international definitions for all the conditions and medications.

“Antithrombotic” must be deciphered. Anti-coagulant term is being used across the review.

6 It looks very raw and superficial at the moment. Would you please elaborate on the content, including options related to the international guidelines The guidelines are entered in table 10